For patients with Barrett’s esophagus who have undergone radiofrequency ablation

Study ID: F/N-R20-3895L

Effect of orally administered vitamin A on the esophageal lining following radiofrequency ablation

Barrett’s esophagus (BE) is a condition that arises from chronic heartburn or gastroesophageal reflux disease and can lead to cancer of the esophagus. Radiofrequency ablation (RFA) is a nonsurgical procedure that uses a spectrum of energy to produce a highly localized heat-like effect on the tissue in order to destroy the dysplastic Barrett’s region.

Researchers seek to determine if treatment with vitamin A can help patients who have been diagnosed with Barrett’s esophagus and who have undergone radiofrequency ablation.

Eligible patients for this clinical trial are randomized into one of two study arms. One group receives treatment with orally administered vitamin A. The other group receives a placebo.

Researchers seek to determine if vitamin A can modify and improve the esophageal lining after RFA. It is theorized that modification of the lining may result in the healed esophageal lining being less affected by refluxed acid.

This prospective, randomized study is to determine if orally administered retinoic acid (5,000 – 10,000 IU) can induce modification of the esophageal lining in patients who have undergone RFA of their Barrett’s tissue. The modification of the new esophageal lining may be less leaky to refluxed acid.

Inclusion Snapshot

  • Must have been diagnosed with BE
  • Must have already undergone RFA at least four weeks before trial enrollment

Contact Information

Lankenau Institute for Medical Research trial

Physician Investigator(s)

Study Locations